BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 32, Issue 10
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study
©Author(s) (or their employer(s)) 2026.
World J Gastroenterol. Mar 14, 2026; 32(10): 113771
Published online Mar 14, 2026. doi: 10.3748/wjg.v32.i10.113771
Figure 1
Full Size Figure Download Figure
Figure 1 Pristimerin alleviates high-dose tamoxifen-induced gastric mucosal pathological damage in spasmolytic polypeptide-expressing metaplasia mice. A: Induction of spasmolytic polypeptide-expressing metaplasia mouse model and pristimerin therapeutic regimen; B: Body weight changes in mice; C: Gross morphological observation of gastric tissues; D: Gastric tissue histology by hematoxylin-eosin staining. Scale bar, 100 μm; E: Gastric mucins detected by alcian blue/periodic acid Schiff staining. Scale bar, 100 μm. dP < 0.0001. Values represent the mean ± SD (n = 6). HDT: High-dose tamoxifen; Pri-L: Low-dose pristimerin; Pri-M: Medium-dose pristimerin; Pri-H: High-dose pristimerin.
Write to the Help Desk
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.